1 / 23

From Outer Space… To Your Doctor’s Office ArterioVision ™ CIMT presented to

From Outer Space… To Your Doctor’s Office ArterioVision ™ CIMT presented to Federal Laboratory Consortium Mid-Atlantic Region Meeting by Medical Technologies International, Inc. Gary F. Thompson, Chairman and CEO. 23 October 2007. Summary.

ulysses-pennington
Download Presentation

From Outer Space… To Your Doctor’s Office ArterioVision ™ CIMT presented to

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. From Outer Space… To Your Doctor’s Office ArterioVision™ CIMT presented to Federal Laboratory Consortium Mid-Atlantic Region Meeting by Medical Technologies International, Inc. Gary F. Thompson, Chairman and CEO 23 October 2007

  2. Summary • We help detect and treat Heart Disease and Stroke. • We do this non-invasively, using existing ultrasound equipment. 2

  3. The Need • Cardiovascular Disease (CVD) = #1 killer in the United States…soon to be worldwide • 1 American dies of CVD every 36 seconds • CVD claims more lives than the next 4 leading causes of death…combined • 66% of unexpected cardiac deaths occur with no prior symptoms 3

  4. Win / Win • ArterioVision™ CIMT complements current standard of care • Clinical pathway for other exams and treatment • Patient Benefits • Improved Practice Financials 4

  5. A Case Presentation • Male, Age 50, Caucasian • Strong family history of CVD • All males died before age 50 • Each had no prior symptoms • Lifetime of Fitness • Amateur athlete • Marathoner since 1975 • Non-smoker 5

  6. A Case PresentationPatient Tests • Weeks before 50th birthday, tested non-invasive procedures & biomarkers • Berkeley Heart Lab Comprehensive Panel • hsCRP • Stress echo • Nuclear perfusion • Genetic testing • CT scan / CCS • Valuable/Standard of Care Tests • All Results Negative / Normal or Better 6

  7. A Case PresentationPatient Event • At age 50, ran L.A. Marathon • Mile 15 developed back pain • Ran until mile 20 • Myocardial infarction LAD • Lost 48% of heart muscle • “It is not what happens to you in life that matters, as much as what you do about it.” –Anonymous 7

  8. A Case Presentation HIPAA – Patient’s Permission – Full Disclosure • Business Boards at Caltech • David Baltimore • Recommendation • Beta test site University Hospital • Did not provide prior history • 15 minutes and $500 • Outcome 8

  9. Initial CIMT Exam – 1996 AGE 50: CIMT Value of 2.043 mm 591% greater risk for heart attack or coronary death ------------------- Tot Chol = 174 HDL = 50 LDL = 101 BP = 110/65 HR = 48 9

  10. MTI &“The Company We Keep” First-Rate Partners Cutting-edge science developed by Caltech, JPL Biomedical Research Program & USC’s Keck School of Medicine Atherosclerosis Research Program Exclusive, perpetual worldwide license 10

  11. Image Acquisition & Analysis Co-Inventors • Robert Selzer • Howard Hodis 11

  12. A Few Other Key MTI Team Members • Kelly Nardoni • Stephen Polly • JoAnne Thompson 12

  13. TV News Segment 13

  14. ArterioVision™ CIMTUnique Features • FDA Clearance: Only device approved for measurement AND risk assessment • Proprietary database of CIMT values from patients asymptomatic for CVD • Works with any brand of ultrasound machine • Makes better use of existing equipment 14

  15. ArterioVision™ CIMT Unique Features • Measures surrogate endpoint of disease • Directly measures vascular damage at the arterial wall level • Automated edge detection using subpixel interpolation • Helps monitor treatment efficacy through serial examinations 15

  16. ArterioVision™ CIMT Unique Features • FDA-Cleared Patient Report • Behavioral Modification Tool • Chronological Age vs. Arterial Age • % Risk for Events • Gets the Patient’s Attention • Increased Patient Compliance 16

  17. ArterioVision™ CIMTAcquisition & Analysis Flexibility Analyze images on dedicated PC loaded with analysis software (provided by MTI) Acquire patient images with any brand ultrasound equipment, using MTI’s patented protocol 17

  18. ArterioVision™ CIMT Analysis Demonstration by Jonathan Mullane, Account Executive 18

  19. Vascular Disease Can Be Reversed 2006 - Age 60 CIMT Value of 1.021 mm • Reduction of CIMT by 50% in 10 years. • How?: • Great MDs & RXs • Serial annual CIMT exams • Other testing continued with same Negative / Normal or better results • No red meat • 2 adult beverages / day 19

  20. Conclusion • NASA/JPL help save lives…on Earth • MTI is growing rapidly • Tell us which doctor you want us to visit • Patient brochures, etc. • “Making a Positive Difference Every Day” 20

  21. Q & A “It is not what happens to you in life that matters, as much as what you do about it.” –Anonymous 21

  22. Summary Studies & Societal Guidelines Appendix 22

  23. Studies • Over 2,700 published, peer-reviewed manuscripts consistently and conclusively link CIMT with: • Subclinical atherosclerosis • Cardiovascular risk factors and CVD; and hence • Potential for future cardiovascular events • Landmark studies showing CIMT is related to the risk of clinical cardiovascular events include: • Salonen, 1993 • Chambless, 1997 • Bots, 1997 • Hodis, 1998 • O’Leary, 1999 • Chambless, 2000 • Lorenz, 2006 • Bibliography available upon request 23

More Related